Literature DB >> 19756737

Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.

Maria Lambropoulou1, Nikolaos Papadopoulos, Grigoris Tripsianis, George Alexiadis, Olga Pagonopoulou, Anastasia Kiziridou, Vassilios Liberis, Stylianos Kakolyris, Ekaterini Chatzaki.   

Abstract

AIM: The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer
METHODS: Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated
RESULTS: The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score
CONCLUSIONS: Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756737     DOI: 10.1007/s00432-009-0673-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

Review 1.  Emerging issues of the expression profiling technologies for the study of gynecologic cancer.

Authors:  Kalliopi I Pappa; Nicholas P Anagnou
Journal:  Am J Obstet Gynecol       Date:  2005-09       Impact factor: 8.661

2.  Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium.

Authors:  S Erkanli; F Kayaselcuk; E Kuscu; T Bagis; F Bolat; A Haberal; B Demirhan
Journal:  Int J Gynecol Cancer       Date:  2006 May-Jun       Impact factor: 3.437

3.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.

Authors:  A Berchuck; G Rodriguez; R B Kinney; J T Soper; R K Dodge; D L Clarke-Pearson; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1991-01       Impact factor: 8.661

4.  Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.

Authors:  J M Bhatavdekar; D D Patel; N G Shah; H H Vora; T P Suthar; P R Chikhlikar; N Ghosh; T I Trivedi
Journal:  Ann Surg Oncol       Date:  2000-05       Impact factor: 5.344

5.  Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma.

Authors:  M Lambropoulou; G Alexiadis; V Limberis; N Nikolettos; G Tripsianis
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

6.  Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma.

Authors:  Rainer Lehner; Takayuki Enomoto; James A McGregor; Laurie Shroyer; Bryan R Haugen; Umarani Pugazhenthi; Kenneth R Shroyer
Journal:  Acta Obstet Gynecol Scand       Date:  2002-02       Impact factor: 3.636

7.  Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.

Authors:  P L Cherchi; V Marras; G Capobianco; G Ambrosini; M D Piga; G M Fadda; N Rosas; S Dessole
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

8.  Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma.

Authors:  Noriyuki Takai; Tami Miyazaki; Masakazu Nishida; Kaei Nasu; Isao Miyakawa
Journal:  Cancer Lett       Date:  2002-10-08       Impact factor: 8.679

9.  Cytoplasmic expression of c-erb-B2 in endometrial carcinomas.

Authors:  Maria Lambropoulou; Dimitrios Stefanou; George Alexiadis; Demetrio Tamiolakis; Grigorios Tripsianis; Ekaterini Chatzaki; Gerasimos P Vandoros; Anastasia Kiziridou; Evropi Papadopoulou; Nikolas Papadopoulos
Journal:  Onkologie       Date:  2007-09-21

10.  Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma.

Authors:  N Karahan; M Güney; S Baspinar; B Oral; N Kapucuoglu; T Mungan
Journal:  Eur J Gynaecol Oncol       Date:  2007       Impact factor: 0.196

View more
  7 in total

1.  The role of Apigenin in testicular damage in experimental ischemia-reperfusion injury in rats.

Authors:  I Skondras; M Lambropoulou; A Tsaroucha; S Gardikis; G Tripsianis; C Simopoulos; G Vaos
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

2.  Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.

Authors:  Anastasia Tsiaousidou; A K Tsaroucha; M Lambropoulou; M Pitiakoudis; A Polychronidis; E Chatzitheoklitos; K Romanidis; C Simopoulos
Journal:  Clin Exp Med       Date:  2015-04-30       Impact factor: 3.984

3.  Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival.

Authors:  Maria Lambropoulou; Theodora-Eleftheria Deftereou; Sryridon Kynigopoulos; Anargyros Patsias; Constantinos Anagnostopoulos; Georgios Alexiadis; Athanasia Kotini; Alexandra Tsaroucha; Christina Nikolaidou; Anastasia Kiziridou; Nikolaos Papadopoulos; Ekaterini Chatzaki
Journal:  Med Oncol       Date:  2015-12-26       Impact factor: 3.064

4.  pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant.

Authors:  A Brunner; P Riss; G Heinze; H Brustmann
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

5.  Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer.

Authors:  Xiaopeng Cai; Shuai Ma; Ming Gu; Cong Zu; Wenzhi Qu; Xinyu Zheng
Journal:  Diagn Pathol       Date:  2012-05-18       Impact factor: 2.644

6.  Expression of matrix metalloproteinase-2 and survivin in endometrioid and nonendometrioid endometrial cancers and clinicopathologic significance.

Authors:  Evren Yilmaz; Meral Koyuncuoglu; Ilknur Bilkay Görken; Emre Okyay; Bahadir Saatli; Emine Cagnur Ulukus; Ugur Saygili
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

7.  Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression.

Authors:  Aggelis Stavropoulos; Michail Varras; Thivi Vasilakaki; Viktoria-Konstantina Varra; Fani-Niki Varra; Aikaterini Tsavari; Aphrodite Nonni; Nikolaos Kavantzas; Andreas C Lazaris
Journal:  Oncol Lett       Date:  2020-05-30       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.